Emma Asma Cornwall
All posts from Emma Asma Cornwall
Emma Asma Cornwall in Emma Asma Cornwall,

Onyx is on news again: its drug gets FDA priority review status

The FDA has given Bayer and Onyx Pharmaceuticals priority review for their application to use their Nexavar (sorafenib) drug against a difficult-to-treat type of thyroid cancer, reports Reuters.

It means that the FDA will complete the review within six months instead of nine. Nexavar is already authorized for use against liver and kidney tumors, and it is being trialled for breast cancer. This development is obviously positive for both companies, and for Amgen too!